Tirzepatide was originally developed to treat type 2 diabetes, but it has also demonstrated protective effects on the cardiovascular system. It is a synthetic analog of gastric inhibitory polypeptide (GIP) that also mimics the actions of glucagon-like peptide-1 (GLP-1). This dual mechanism helps reduce blood glucose levels, enhance insulin sensitivity, and promote a sense of satiety.